In type 2 diabetes, limited prospective evidence does support tight glycemic control to help prevent or slow the progression of microvascular and neuropathic complications. It is uncertain whether tight glycemic control decreases macrovascular complications and which pharmacotherapeutic agent(s) is/are the best options. However, therapy that improves glucose control in combination with aggressive risk factor management should be initiated and enforced in patients with type 2 diabetes in an effort to reduce long-term complications.

KEY WORDS cefuroxime axetil; antimicrobial; uncomplicated gonorrhea efuroxime axetil (Ceftin(R), Glaxo Wellcome, Research Triangle Park, NC) is the oral prodrug formulation of the injectable antibiotic cefuroxime sodium. It has essentially the same antibacterial activity as its parent moiety, making cefuroxime the only second-generation cephalosporin with both an intravenous and oral formulation. STRUCTURE AND DERIVATION Cefuroxime axetil is the 1-acetoxyethyl ester of cefuroxime. The axetil salt renders the molecule more lipophilic, thus allowing enhanced oral absorption. Once cefuroxime axetil reaches the intestinal mucosa and portal blood flow it rapidly undergoes de-esterification to yield the active parent compound cefuroxime. MECHANISM OF ACTION Cefuroxime axetil is a second-generation cephalosporin that contains the classic [3-1actam ring struc

No abstract